MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model

Pharmaceutical Research

Volumn 29, Issue 4, 2012, Pages 953-960

  Tan, Mingqian ^a,b   Burden Gulley, Susan M ^c   Li, Wen ^a   Wu, Xueming ^a   Lindner, Daniel ^d   Brady Kalnay, Susann M ^c   Gulani, Vikas ^c   Lu, Zheng Rong ^a,c  

^a Case Western Reserve University   (United States)

^b DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Molecular imaging; MRI; Prostate cancer; Targeted contrast agent; Tumor stroma

Indexed keywords

CLT1 PEPTIDE GADOTERIC ACID MONOAMIDE CONJUGATE; FIBRIN; FIBRONECTIN; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; FLUORESCENCE IMAGING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; CARBOCYANINES; CELL LINE, TUMOR; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; FIBRIN; FIBRONECTINS; FLUORESCENT DYES; HETEROCYCLIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, NUDE; MOLECULAR IMAGING; NANOPARTICLES; ORGANOMETALLIC COMPOUNDS; PEPTIDES, CYCLIC; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84862650648     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0635-y     Document Type: Article

References (25)

1. Weissleder R. Molecular imaging in cancer. Science. 2006;312: 1168-71.
2. YallapuMM, Foy SP, Jain TK, Labhasetwar V. PEG-functionalized magnetic nanoparticles for drug delivery and magnetic resonance imaging applications. Pharm Res. 2010;27:2283-95.
3. Cheng Z, Thorek DL, Tsourkas A. Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agent. Angew Chem Int Ed Engl. 2010;49:346-50.
4. Pan D, Caruthers SD, Chen J,Winter PM, Senpan A, Schmieder AH, Wickline SA, LanzaGM.Nanomedicine strategies for molecular targets with MRI and optical imaging. Future Med Chem. 2010;2:471-90.
5. 3-targeted magnetic resonance imaging. Nat Med. 1998;4:623-6.
6. 2 fragments as potential immunocontrast agents. Relaxometry, biodistribution, and magnetic resonance imaging in nude mice grafted with human colorectal carcinoma. Invest Radiol. 1998;33:752-61.
7. Ke T, Jeong E, Wang X, Feng Y, Parker D, Lu Z. RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker alpha(v)beta(3) integrin with MRT1 mapping. Int J Nanomed. 2007;2:191-9.
8. Artemov D, Mori N, Ravi R, Bhujwalla Z. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res. 2003;63:2723-7.
9. Caravan P, Das B, Dumas S, Epstein FH, Helm PA, Jacques V, Koerner S, Kolodziej A, Shen L, Sun WC, Zhang Z. Collagen-targeted MRI contrast agent for molecular imaging of fibrosis. Angew Chem Int Ed Engl. 2007;46:8171-3.
10. Boutry S, Burtea C, Laurent S, Toubeau G, Vander Elst L, Muller RN. Magnetic resonance imaging of inflammation with a specific selectin-targeted contrast agent. Magn Reson Med. 2005;53:800-7.
11. Sirol M, Fuster V, Badimon JJ, Fallon JT, Moreno PR, Toussaint JF, Fayad ZA. Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation. 2005;112:1594-600.
12. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, Leprini A, Borsi L, Castellani P, Zardi L, Neri D, Riva P. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res. 2003;9:571-9.
13. Sönmez H, Süer S, Karaarslan I, Baloǧlu H, Kökoǧlu E. Tissue fibronectin levels of human prostatic cancer, as a tumor marker. Canc Biochem Biophys. 1995;15:107-10.
14. Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. Int J Cancer. 2006;118:1331-9.
15. Pilch J, Brown D, Komatsu M, Järvinen TA, Yang M, Peters D, Hoffman RM, Ruoslahti E. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc Natl Acad Sci U S A. 2006;103:2800-4.
16. Ye F, Jeong E, Jia Z, Yang T, Parker D, Lu Z. A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI. Bioconjugate Chem. 2008;19:2300-3.
17. Tan M, Wu X, Jeong E, Chen Q, Lu Z. Peptide-targeted nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging. Biomacromolecules. 2010;11:754-61.
18. Mahato R, Qin B, Cheng K. Blocking IKKα expression inhibits prostate cancer invasiveness. Pharm Res. 2011;28:1357-69.
19. Lee CM, Jeong HJ, Cheong SJ, Kim EM, Kim DW, Lim ST, Sohn MH. Prostate cancer-targeted imaging using magnetofluorescent polymeric nanoparticles functionalized with bombesin. Pharm Res. 2010;27:712-21.
20. Wu X, Feng Y, Jeong EK, Emerson L, Lu ZR. Tumor characterization with dynamic contrast enhanced magnetic resonance imaging and biodegradable macromolecular contrast agents in mice. Pharm Res. 2009;26:2202-8.
21. Işisaǧ A, Neşe N, Ermete M, Lekili M, Ayhan S, Kandiloǧlu AR. Col IV and Fn distribution in prostatic adenocarcinoma and correlation of 67LR, MMP-9 and TIMP-1 expression with Gleason score. Anal Quant Cytol Histol. 2003;25:263-72.
22. Desai B, Elatre W, Quinn DI, Jadvar H. FDG PET/CT demonstration of pancreatic metastasis from prostate cancer. Clin Nucl Med. 2011;36:961-2.
23. Pinkawa M, Eble MJ, Mottaghy FM. PET and PET/CT in radiation treatment planning for prostate cancer. Expert Rev Anticancer Ther. 2011;11:1035-41.
24. Rieter WJ, Keane TE, Ahlman MA, Ellis CT, Spicer KM, Gordon LL. Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer. Clin Nucl Med. 2011;36:872-8.
25. Schuster DM, Savir-Baruch B, Nieh PT, Master VA, Halkar RK, Rossi PJ, Lewis MM, Nye JA, Yu W, Bowman FD, Goodman MM. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology. 2011;259:852-61.